Screener
Regenxbio RGNX Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue (Gross) by Product | ||||||
| Abb Vie Development Milestone | $100M— | —— | —— | —— | —— | |
| Nippon Shinyaku Services | $3.72M+36.8% | $1.01M-43.0% | $1.4M— | $5.93M— | $2.72M— | |
| Other Service Revenue | $458K+163% | $292K+54.5% | $1.79M+321% | $196K-8.8% | $174K-61.2% | |
| Zolgensma And Itvisma Royalties | $3.84M-79.2% | $5.05M-70.3% | —— | —— | $18.42M-9.6% |
FAQ
- How does Regenxbio break its business down?
- Regenxbio (RGNX) reports revenue (gross) by product across 4 parts — Abb Vie Development Milestone, Nippon Shinyaku Services, Other Service Revenue and Zolgensma And Itvisma Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Regenxbio's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Regenxbio's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
